Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-10-14
2009-02-17
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reexamination Certificate
active
07491390
ABSTRACT:
Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
REFERENCES:
patent: 5573924 (1996-11-01), Beckmann et al.
patent: 6214345 (2001-04-01), Firestone et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6884869 (2005-04-01), Senter et al.
patent: 2003/0083263 (2003-05-01), Doronina et al.
patent: 2003/0096743 (2003-05-01), Senter et al.
patent: 2003/0130189 (2003-07-01), Senter et al.
patent: 2004/0157782 (2004-08-01), Doronina et al.
patent: 2005/0113308 (2005-05-01), Senter et al.
patent: 2005/0118656 (2005-06-01), Terrett
patent: 2005/0123547 (2005-06-01), Terrett
patent: 2005/0191299 (2005-09-01), Swamy et al.
patent: 2005/0238649 (2005-10-01), Doronina et al.
patent: 2006/0074008 (2006-04-01), Senter et al.
patent: 2006/0083736 (2006-04-01), Law et al.
patent: WO 01/94629 (2001-12-01), None
patent: WO 02/088172 (2002-11-01), None
patent: WO 03/026577 (2003-04-01), None
patent: WO 03/046581 (2003-06-01), None
patent: WO 2004/010957 (2004-02-01), None
patent: WO 2004/007356 (2004-09-01), None
patent: WO 2004/007356 (2004-09-01), None
patent: WO 2004/073656 (2004-09-01), None
patent: WO 2005/081711 (2005-09-01), None
patent: WO 2006/044643 (2006-04-01), None
patent: WO 2006/113909 (2006-10-01), None
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.
Rudikoff et al., Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.
Coleman P. M., Research in Immunology, 145:33-36, 1994.
MacCallum et al., J. Mol. Biol., 262, 732-745, 1996.
Casset et al, Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Agathanggelou et al., “Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells,”Am J. Pathol., 147(4):1152-1160 (1995).
Agematsu et al., “Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction,”Blood, 91(1):173-180 (1998).
Agematsu et al., “B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production,”Eur. J. Immunol., 27(8):2073-2079 (1997).
Akiba et al., “Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis,”J. Exp. Med., 191(2):375-380 (2000).
Bahler et al., “Clonal evolution of a follicular lymphoma: evidence for antigen selection,”PNAS, 89(15):6770-6774 (1992).
Bahler et al., “Antigen selection in human lymphomagenesis,”Cancer Res., 52(19 Suppl.):5547s-5551s (1992).
Bowman et al., “The cloning of CD70 and its identification as the ligand for CD27,”J. Immunol., 152(4):1756-1761 (1994).
Brugnoni et al., “CD70 expression on T-cell subpopulations: study of normal individuals and patients with chronic immune activation,”Immunol. Lett., 55(2):99-104 (1997).
De Jong et al., “Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptor,”J. Immunol., 146(8):2488-2494 (1991).
Den Haan et al., “Identification of a graft verus host disease-associated human minor histocompatibility antigen,”Science, 268(5216):1476-1480 (1995).
Dillman, R. O., “Monoclonal Antibodies for Treating Cancer,”Ann. Int. Med., 111:592-603 (1989).
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,”Nature Biotechnology, 21(7):778-784 (2003) + erratum: 21(8):941 (2003).
Giralt et al., “Leukemia relapse after allogeneic bone marrow transplantation: a review,”Blood, 84(11):3603-3612 (1994).
Goodwin et al., “Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor,”Cell, 73(3):447-456 (1993).
Gravestein et al., “Cloning and expression of murine CD27: comparison with 4-1BB, another lymphocyte-specific member of the nerve growth factor receptor family,”Eur. J. Immunol., 23(4):943-950 (1993).
Gravestein et al., “Novel mAbs reveal potent co-stimulatory activity of murine CD27,”Int. Immunol., 7(4):551-557 (1995).
Gruss et al., “Pathophysiology of Hodgkin's disease: functional and molecular aspects,”Baillieres Clin. Haematol., 9(3):417-446 (1996).
Held-Feindt et al., “CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors,”Int. J. Cancer, 98(3):352-356 (2002).
Hintzen et al., “CD70 represents the human ligand for CD 27,”Int. Immunol., 6(3):477-480 (1994).
Hintzen et al., “Characterization of the human CD27 ligand,a novel member of the TNF gene family,”J. Immunol., 152(4):1762-773 (1994).
Hintzen et al., “CD27: marker and mediator of T-cell activation?,”Immunol. Today, 15(7):307-311 (1994).
Hintzen et al., “Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation,”J. Immunol., 154(6):2612-2623 (1995).
Hintzen et al., “Regulation of CD27 expression on subsets of mature T-lymphocytes,”J. Immunol., 151(5):2426-2435 (1993).
Hintzen et al., “A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex,”J. Immunol., 147(1):29-35 (1991).
Hishima et al., “CD70 expression in thymic carcinoma,”Am J. Surg. Pathol., 24(5):742-746 (2000).
Jacquot et al., “CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling,”J. Immunol., 159(6):2652-2657 (1997).
Kobata et al., “CD27-CD70 interactions regulate B-cell activation by T cells,”PNAS, 92(24):11249-11253 (1995).
Lens et al., “Aberrant expression and reverse signaling of CD70 on malignant B cells,”Br. J. Haematol., 106(2):491-503 (1999).
Lens et al., “Phenotype and function of human B cells expressing CD70 (Cd27 ligand),”Eur. J. Immunol., 26(12):2964-2971 (1996).
Lens et al., “Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells,”Immunol., 90:38-45 (1997).
Lens et al., “Control of lymphoctye function through CD27-CD70 interactions,”Semin Immunol., 10(6):491-499 (1998).
Locksley et al., “The TNF and TNF receptor superfamilies: integrating mammalian biology,”Cell, 104(4):487-501 (2001).
Maurer et al., “CD27 expression by a distinct subpopulation of human B lymphocytes,”Eur. J. Immunol., 20(12):2679-2684 (1990).
Nakajima et al., “Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis,”J. Neuroimmunol., 109(2):188-196 (2000).
Nakajima et al., “Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice,”J. Immunol., 158(3):1466-1472 (1997).
Oelke et al., “Overexpression of CD70 and Overstimulation of IgG Synthesis by Lupus T Cells and T Cells Treated With DNA Methylation Inhibitors,”Arthritis&Rheumatism, 50(6):1850-1860 (2004).
Orengo et al., “Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity,”Clin. Exp. Immunol., 107(3):608-613 (1997).
Oshima et al., “Characterization of murine CD70 by molecular cloning and mAb,”Int. Immunol., 10(4):517-526 (1998).
Peitsch et al.,
Law Che-Leung
McEarchern Julie
Wahl Alan F.
Halvorson Mark
Seattle Genetics Inc.
Townsend and Townsend / and Crew LLP
Yu Misook
LandOfFree
Anti-CD70 antibody and its use for the treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CD70 antibody and its use for the treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD70 antibody and its use for the treatment and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4112429